最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
分子式C19H19NOS |
InChIKeyZCVMWBYGMWKGHF-UHFFFAOYSA-N |
CAS号34580-13-7 |
开始日期2023-12-15 |
申办/合作机构 |
开始日期2023-04-20 |
申办/合作机构 |
开始日期2022-12-01 |
申办/合作机构 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
季节性过敏性结膜炎 | 瑞典 | 2000-10-31 | |
皮炎 | 日本 | 1986-04-30 | |
湿疹 | 日本 | 1986-04-30 | |
瘙痒 | 日本 | 1986-04-30 | |
荨麻疹 | 日本 | 1986-04-30 | |
哮喘 | 瑞士 | 1979-05-03 | |
慢性荨麻疹 | 瑞士 | 1979-05-03 | |
变应性结膜炎 | 瑞士 | 1979-05-03 | |
特应性皮炎 | 瑞士 | 1979-05-03 | |
过敏性鼻炎 | 瑞士 | 1979-05-03 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | - | 鏇衊鬱簾蓋鏇鏇積範繭(膚鬱繭廠襯壓鏇鹽範鏇) = 願窪憲壓鑰鹽顧糧壓壓 觸網遞鏇淵顧選築鏇積 (選壓鏇積夢選網糧獵獵 ) | - | 2018-10-01 | |||
鏇衊鬱簾蓋鏇鏇積範繭(膚鬱繭廠襯壓鏇鹽範鏇) = 鬱鹹網觸窪膚簾簾醖鑰 觸網遞鏇淵顧選築鏇積 (選壓鏇積夢選網糧獵獵 ) | |||||||
N/A | 花生过敏 eosinophilia | 6 | 願夢獵窪築廠製遞鬱獵(窪繭簾獵顧鹽網齋窪淵) = 3 anaphylactic reactions occurred: day-1 placebo patient at 50mg dose (gastrointestinal, cutaneous); day-5 treatment patient at 50mg dose, occurred post exercise, (gastrointestinal, cutaneous, respiratory); day-6 placebo patient at 12mg dose, associated with fever, (gastrointestinal, cutaneous, respiratory), epinephrine was given and patient withdrew from study 獵築簾窪繭艱獵衊齋繭 (艱獵觸願鏇壓鑰顧壓築 ) 更多 | 积极 | 2012-02-01 | ||
Placebo | |||||||
N/A | 99 | Epinastine HCl 0.05% | (夢願觸夢糧廠遞餘範鹽) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 窪構膚願壓襯憲鹹糧鬱 (簾顧夢膚壓蓋積範觸壓 ) | - | 2004-05-01 | ||
N/A | 变应性结膜炎 HLA-DR+ | CD29+ | eotaxin+ | 19 | (廠廠選繭艱壓艱築蓋顧) = 鹽襯顧醖簾鏇醖鹹築壓 顧壓製壓顧遞範網網窪 (構艱鹽鑰鹽夢構範襯範 ) 更多 | 积极 | 2003-05-01 | ||
N/A | 92 | 獵顧餘顧鬱襯製繭網築(蓋顧艱憲襯顧艱製網鹽) = 壓範構鑰遞願窪網餘願 鏇廠蓋餘衊齋廠網壓築 (蓋構衊齋願襯壓襯膚顧 ) | - | 2003-05-01 | |||
Olopatadine HCl 0.1% | 獵顧餘顧鬱襯製繭網築(蓋顧艱憲襯顧艱製網鹽) = 鹹鹽淵窪糧醖膚觸遞襯 鏇廠蓋餘衊齋廠網壓築 (蓋構衊齋願襯壓襯膚顧 ) |